AU2007249761A1 - CDKI pathway inhibitors as selective inhibitors of tumor cell growth - Google Patents

CDKI pathway inhibitors as selective inhibitors of tumor cell growth Download PDF

Info

Publication number
AU2007249761A1
AU2007249761A1 AU2007249761A AU2007249761A AU2007249761A1 AU 2007249761 A1 AU2007249761 A1 AU 2007249761A1 AU 2007249761 A AU2007249761 A AU 2007249761A AU 2007249761 A AU2007249761 A AU 2007249761A AU 2007249761 A1 AU2007249761 A1 AU 2007249761A1
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
cdk3
snx9
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007249761A
Other languages
English (en)
Inventor
Bey-Dih Chang
Donald Porter
Igor B. Roninson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senex Biotechnology Inc
Original Assignee
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc filed Critical Senex Biotechnology Inc
Publication of AU2007249761A1 publication Critical patent/AU2007249761A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007249761A 2006-05-15 2007-05-15 CDKI pathway inhibitors as selective inhibitors of tumor cell growth Abandoned AU2007249761A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74722006P 2006-05-15 2006-05-15
US60/747,220 2006-05-15
US84996806P 2006-10-06 2006-10-06
US60/849,968 2006-10-06
PCT/US2007/011622 WO2007133772A2 (en) 2006-05-15 2007-05-15 Cdki pathway inhibitors as selective inhibitors of tumor cell growth

Publications (1)

Publication Number Publication Date
AU2007249761A1 true AU2007249761A1 (en) 2007-11-22

Family

ID=38694543

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007249761A Abandoned AU2007249761A1 (en) 2006-05-15 2007-05-15 CDKI pathway inhibitors as selective inhibitors of tumor cell growth

Country Status (6)

Country Link
US (1) US20080200531A1 (enExample)
EP (1) EP2023925A4 (enExample)
JP (1) JP2009537532A (enExample)
AU (1) AU2007249761A1 (enExample)
CA (1) CA2652339A1 (enExample)
WO (1) WO2007133772A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN103468786B (zh) * 2012-06-06 2017-06-13 上海吉凯基因化学技术有限公司 人cdkl3基因的用途及其相关药物
WO2014089450A1 (en) 2012-12-06 2014-06-12 Senex Biotechnology, Inc. Specific inhibitors of cdk3
US10584369B2 (en) * 2013-01-11 2020-03-10 Senex Biotechnology, Inc. Cell-based methods for measuring activity of a protein inhibitor
CA2928429C (en) 2013-10-28 2022-08-30 Drexel University Aminoalkyl phenyl derivatives useful in the treatment of adhd and other cognitive disorders
US11013728B2 (en) 2017-04-03 2021-05-25 Kyoto Pharmaceutical Industries, Ltd. Cyclin-dependent kinase 8 and/or 19 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915990A (en) * 1973-03-13 1975-10-28 Nelson Res & Dev Tryptamines
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
ES2213996T3 (es) * 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
AU2004271730A1 (en) * 2003-09-18 2005-03-24 Novartis Ag Combination of a histone deacetylase inhibitor with a death receptor ligand
JP2008540586A (ja) * 2005-05-18 2008-11-20 フォルシュングスフェアブント ベルリン エー ファウ Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤

Also Published As

Publication number Publication date
WO2007133772A3 (en) 2008-11-20
EP2023925A4 (en) 2011-02-16
WO2007133772A2 (en) 2007-11-22
CA2652339A1 (en) 2007-11-22
JP2009537532A (ja) 2009-10-29
EP2023925A2 (en) 2009-02-18
US20080200531A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
Pan et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
US20080033000A1 (en) Identification of CDKI pathway inhibitors
US20100190807A1 (en) CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
US20200048208A1 (en) TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
US20080200531A1 (en) CDKI pathway inhibitors as inhibitors of tumor cell growth
JP2014055135A (ja) 複合的癌治療の方法、組成物および標的
KR20150023223A (ko) Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
US20090281129A1 (en) Cdki pathway inhibitors and uses thereof
Yousefi et al. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming
Wang et al. DpdtbA‐Induced Growth Inhibition in Human Esophageal Cancer Cells Involved Inactivation of the p53/EGFR/AKT Pathway
Kim et al. A drug‐repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6‐thioguanine as an effective therapeutic agent for TPMT‐low cancer cells
US11267809B2 (en) BAF complex modulating compounds and methods of using the same
Müller et al. Targeting cancer stem cells with small molecules
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
US11980594B2 (en) Composition and method for treating a drug-resistant cancer
Liang et al. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone
Ivorra et al. Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease
KR101168054B1 (ko) 오토파지 관련 질환의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝방법
US20180256587A1 (en) A Synthetic Lethal Drug Combination for Treating Renal Cell Carcinoma
CN102791261A (zh) 用于治疗肾细胞癌的化合物
Helderman et al. GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells
Subeha et al. Nelfinavir induces cytotoxicity towards high-grade serous ovarian cancer cells regardless of platinum sensitivity, involving induction of the unfolded protein response, modulation of protein synthesis, DNA damage, lysosomal impairment, and potentiation of toxicity caused by proteasome inhibition
WO2014089450A1 (en) Specific inhibitors of cdk3
Meier et al. Let us know how access to this document benefits you.

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application